Updated strategies and new insights into tuberculosis and mpox treatment were a major focus at the 2025 Conference on Retroviruses and Opportunistic Infections, headlined by findings that high-dose rifampicin plus levofloxacin increased early mortality in hospitalized people with HIV with disseminated tuberculosis, whereas tecovirimat demonstrated no efficacy for clade II mpox.
Herein, we summarize clinically relevant updates related to tuberculosis, mpox, Kaposi sarcoma, human papillomavirus, and other HIV-associated infectious complications presented at the conference.
